Pediatric Vaccine Market Growth to register a CAGR of 14.4% to reach US$ 98,859.3 Million By 2027 | Generated Opportunities for Growth

Pneumococcal conjugate vaccination is recommended for all children under the age of two, according to the Centers for Disease Control and Prevention (CDC). Hepatitis B vaccine, flu vaccine, and human papillomavirus vaccine are among the other immunizations available for newborns. The global pediatric vaccine market is estimated to account for US$ 37,567 Mn in terms of value in 2019 and is expected to reach US$ 98,859 Mn by the end of 2027.

Request for Analysis of COVID-19 Impact on Pediatric Vaccines Market –
https://www.coherentmarketinsights.com/insight/request-sample/1708

Market: Drivers

Increased funding for vaccines is expected to drive the global paediatric vaccines market’s growth. For example, Codagenix, a business focused on vaccination and viral therapy R&D, raised US$ 20 million in a new round of financing headed by Adjuvant Capital in January 2020.

Market: Opportunities

Players in the market may concentrate on introducing important vaccines in underdeveloped countries. In such areas, TB is extremely common. Furthermore, rising antibiotic resistance in tuberculosis treatment is likely to provide attractive growth possibilities for market competitors.

Market: Restraints

Some countries have a high level of vaccine mistrust, which is projected to restrict market expansion. According to The Wellcome Trust’s Wellcome Global Monitor (2019), Gabon (26 percent), Togo (25 percent), Russia (24 percent), Austria (21 percent), and Iceland (21 percent) have the highest levels of vaccination safety mistrust.

Key Takeaways:

Pneumococcal Vaccine sub segment in the vaccine type segment in global pediatric vaccines market was valued at US$ 10,299.7 Mn in 2018 and is expected to reach US$ 36,120.1 Mn by 2027 at a CAGR of 14.4% during the forecast period.

A notable growth factor for the market is likely to be the growing engagement between the Global Alliance for Vaccinations and Immunization (GAVI) and key vendors to supply pneumococcal vaccines in emerging countries. For example, GSK (Glaxo Smith Kline) announced in March 2016 the release of pneumococcal vaccine at the lowest price – US$ 3.05 starting in 2017, a 10% drop from the 2016 price.

In terms of value, the conjugate vaccines category dominated the worldwide paediatric vaccine market in 2018, accounting for 30.0 percent of the market, followed by live vaccines and inactivated vaccines. The global conjugate vaccine market is likely to develop as more meningococcal conjugate vaccine candidates are approved.

Furthermore, development of multivalent conjugate vaccines by key players is expected to drive growth of global conjugate vaccine market. For instance, in September 2018, Pfizer, Inc. received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077.

Request PDF Brochure Report –
https://www.coherentmarketinsights.com/insight/request-pdf/1708

Market Trends

Clinical trials are a priority for the market’s major players as they seek to extend their product portfolio. Takeda Pharmaceutical Company Limited, for example, stated in November 2019 that the primary endpoint analysis of its Phase 3 Tetravalent Immunization against Dengue Efficacy Study trial of its dengue vaccine candidate (TAK-003) has been published in the New England Journal of Medicine. The development of novel vaccines is also a priority for the market’s major participants. NewLink Genetics Corporation, for example, gained European Commission (EC) clearance in November 2019 to market ERVEBO or Zaire Ebola virus vaccine V920 in 31 European countries.

Competitive Landscape

GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Sanofi, Pancea Biotec, Zydua Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech, and Indian Immunologicals Ltd. are among the major competitors in the worldwide paediatric vaccine market.

Key Developments

In December 2019, Y-mAbs Therapeutics Inc. received a Rare Pediatric Disease Designation status for its GD2-GD3 vaccine for the treatment of neuroblastoma, from the U.S. FDA

In December 2019, Seqirus received approval for its cell-based quadrivalent influenza vaccine FLUCELVAX QUAD for the protection against four influenza virus strains — A(H3N2), A(H1N1) and two B virus strains, from Health Canada

Reasons to Purchase this Report

Current and future of global Pediatric Vaccines market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

Regions/countries that are expected to witness the fastest growth rates during the forecast period

The latest developments, market shares, and strategies that are employed by the major market players

Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/1708

Segmentation:

By Vaccine Type:

• • Pneumonococcal Vaccine
  • DTP Vaccine
  • Rotavirus Vaccine
  • MMR Vaccine
  • Polio Vaccine
  • Influenza Vaccine
  • Hepatitis B Vaccine
  • Meningococcal Vaccine
  • Hib Vaccine
  • Varicella Vaccine

By Technology:

• • Live or Attenuated Vaccine
  • Inactivated or Killed Vaccine
  • Toxoid Vaccine
  • Conjugate Vaccine
  • Subunit Vaccine
  • Recombinant Vaccine

By Type:

• • Monovalent Vaccine
  • Multivalent Vaccine

By Distribution Channel:

• • Government
  • Private

Company Profiles

• • • • • • • • • GlaxoSmithKline Plc.*
                  • Company Overview
                  • Product Portfolio
                  • Financial Performance
                  • Key Strategies
                  • Recent Developments
                • Merck & Co., Inc.
                • Pfizer Inc.
                • Sanofi S.A.
                • Panacea Biotec
                • Zydus Cadila
                • Emergent BioSolutions Inc.
                • Serum Institute of India Pvt. Ltd.
                • Bharat Biotech
                • Indian Immunologicals Ltd.

Table of Content

Global Pediatric Vaccines Market Research Report

Section 1: Global Pediatric Vaccines Industry Overview

Section 2: Global Economic Impact on Pediatric Vaccines Industry

Section 3: Global Market Competition by Industry Producers

Section 4: Global Productions, Revenue (Value), according to Regions

Section 5: Global Supplies (Production), Consumption, Export, Import, geographically

Section 6: Global Productions, Revenue (Value), Price Trend, Product Type

Section 7: Global Market Analysis, on the basis of Application

Section 8: Pediatric Vaccines Market Pricing Analysis

Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers

Inquire more about this report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/1708

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837